Richard Mattson, MD
Professor Emeritus of NeurologyCards
About
Titles
Professor Emeritus of Neurology
Adjunct Professor of Nursing, Yale Nursing School
Biography
Dr Mattson was born and raised in Connecticut, attended and received a BS degree from Yale University followed by his M.D. from Boston University. He did his neurology residency and a clinical neurophysiology fellowship at the Mayo Clinic in Rochester, MN. While there he did research on interruption of the spread of epileptic seizures in an animal models and received an M.S. degree.
Following his formal training Dr. Mattson spent five more years with the USAF in San Antonio, TX. During that time he and his colleagues did the original studies on the effect of sleep deprivation on the occurrence of epileptic seizures and as an activating technique in EEG.
In 1967 Dr. Gilbert Glaser, M.D., Professor and Chair of Neurology, recruited him to the faculty at the Yale School of Medicine primarily to develop one of the world’s first Epilepsy Intensive Monitoring Units and they founded what is now known as the Yale Comprehensive Epilepsy Center.
His special area of interest increasingly turned toward antiepileptic drug therapy. He directed the two largest multi-center (VA Coop) studies that defined the effectiveness and adverse effects of the standard antiepileptic drugs (AEDs). He continues to be active in development and evaluation the new AEDs. For almost two decades Dr. Mattson directed the Yale/NIH Program Project that studied both clinical and basic aspects of epilepsy.
He has authored or co-authored more than 250 original papers, reviews and chapters most in the field of epilepsy and is co-editor of a number of books including the standard reference, Antiepileptic Drugs. He has been invited to speak throughout the world on the topic of epilepsy.
In addition Dr Mattson has been active in education and was former Vice Chairman for Academic Affairs in Neurology as well as Director of the Yale Neurology Residency Program and the founder and first Director of Clinical Neuroscience Education and Clerkship at Yale School of Medicine. He also for 20 years has chaired the J. Kiffin Penry Epilepy Minifellowships, the largest postgraduate Educational Epilepsy Program in the USA.
Dr Mattson has been the President of the American Epilepsy Society. He has been recognized with a number of prizes and awards including The William Lennox Award of the American Epilepsy Society, the Novartis/ILAE Epileptology Prize, The Hans Berger Award, The Clinical Investigator Award of American Epilepsy Society/Milken Family Foundation and the Hans Berger Distinguished Scholar Award He is recognized by Who’ Who in the World and Best Doctors in America.
Dr. Mattson continues to be active in teaching and clinical care of adults and children with epilepsy.
Appointments
Other Departments & Organizations
Education & Training
- MS
- Mayo Medical School (Univ. of Minnesota), neurology (neurophysiology) (1962)
- Fellow
- Mayo Clinic (1962)
- Resident
- Mayo Clinic (1962)
- MD
- Boston University (1957)
- BS
- Yale College, Zoology (1953)
Board Certifications
Neurology
- Certification Organization
- AB of Psychiatry & Neurology
- Original Certification Date
- 1964
Research
Publications
2015
A Novel KCNQ2 Mutation in a Child with Benign Familial Neonatal Seizures and Rolandic Epilepsy
Szekely A, Mattson R, Manganas L. A Novel KCNQ2 Mutation in a Child with Benign Familial Neonatal Seizures and Rolandic Epilepsy. Journal Of Pediatric Epilepsy 2015, 05: 037-041. DOI: 10.1055/s-0035-1567850.Peer-Reviewed Original Research
2014
Epilepsy Treatment Strategies
Detyniecki K, Farooque P, Mattson R. Epilepsy Treatment Strategies. 2014, 173-174. DOI: 10.1016/b978-0-12-385157-4.00278-5.Peer-Reviewed Original ResearchEpilepsy; Antiepileptic Drug Profiles
Farooque P, Detyniecki K, Mattson R. Epilepsy; Antiepileptic Drug Profiles. 2014, 81-92. DOI: 10.1016/b978-0-12-385157-4.00279-7.Peer-Reviewed Original ResearchEpilepsy; Drug Treatment Principles
Mattson R, Detyniecki K, Farooque P. Epilepsy; Drug Treatment Principles. 2014, 103-107. DOI: 10.1016/b978-0-12-385157-4.00283-9.Peer-Reviewed Original Research
2013
Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes
Glauser T, Ben‐Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kälviäinen R, Mattson R, French J, Perucca E, Tomson T, Guidelines F. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013, 54: 551-563. PMID: 23350722, DOI: 10.1111/epi.12074.Peer-Reviewed Original ResearchConceptsLevel of evidencePartial-onset seizuresInitial monotherapyAntiepileptic drugsEfficacy/effectivenessOnset seizuresSuperiority studyValproic acidEvidence reviewEffectiveness evidencePatients' antiepileptic drugsSeizures/epilepsySpecific seizure typesLong-term efficacyAntiepileptic drug efficacyChildhood absence epilepsyUntreated epilepsySeizure typesTreat analysisEpilepsy reportStudy treatmentNoninferiority studyTreatment recommendationsAbsence epilepsyAbsence seizures
2010
Adverse effects of antiepileptic drugs: a brief overview of important issues
Cramer J, Mintzer S, Wheless J, Mattson R. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Review Of Neurotherapeutics 2010, 10: 885-891. PMID: 20518605, DOI: 10.1586/ern.10.71.Peer-Reviewed Original ResearchConceptsAntiepileptic drugsAdverse effectsThird-generation antiepileptic drugPrevalent adverse effectsInadequate seizure controlLack of tolerabilityUnacceptable adverse effectsAED regimenSeizure controlPharmacodynamic toleranceEarly treatmentCNS effectsCommon reasonTreatment retentionSpecific drugsDrugsMedicationsMonotherapyTolerabilityRegimenInitiationDoseSeverity
2007
What constitutes high quality of care for adults with epilepsy?
Pugh M, Berlowitz D, Montouris G, Bokhour B, Cramer J, Bohm V, Bollinger M, Helmers S, Ettinger A, Meador K, Fountain N, Boggs J, Tatum W, Knoefel J, Harden C, Mattson R, Kazis L. What constitutes high quality of care for adults with epilepsy? Neurology 2007, 69: 2020-2027. PMID: 17928576, DOI: 10.1212/01.wnl.0000291947.29643.9f.Peer-Reviewed Original ResearchConceptsQuality of careNational clinical guidelinesPatient focus groupsCare of adultsGeneral neurology clinicValid quality indicatorsHigh-quality careAssessment of qualityNeurology clinicPrimary careClinical guidelinesPatients' perceptionsNeurology careSystematic reviewQuality careEpilepsyQuality indicatorsDisease statesCareExpert panelMost careAdultsExpert opinionFocus groupsPoor understanding
2006
ILAE Treatment Guidelines: Evidence‐based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes
Glauser T, Ben‐Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T. ILAE Treatment Guidelines: Evidence‐based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes. Epilepsia 2006, 47: 1094-1120. PMID: 16886973, DOI: 10.1111/j.1528-1167.2006.00585.x.Peer-Reviewed Original ResearchConceptsPartial-onset seizuresAntiepileptic medicationsInitial monotherapyEvidence-based guidelinesSeizure typesUntreated epilepsyEffectiveness evidenceEpilepsy syndromesTreatment durationClass IClass I evidenceSeizures/epilepsySignificant methodologic problemsWeeks treatment durationOpen-label trialClass II evidenceClass III evidenceClinical trial evidenceLong-term efficacyDifferent seizure typesQuality of evidenceAdverse effects dataAntiepileptic drug efficacyClass II studiesClass III studies
2005
Epidemiological and medical aspects of epilepsy in the elderly
Cloyd J, Hauser W, Towne A, Ramsay R, Mattson R, Gilliam F, Walczak T. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Research 2005, 68: 39-48. PMID: 16384689, DOI: 10.1016/j.eplepsyres.2005.07.016.Peer-Reviewed Original ResearchConceptsElderly patientsStatus epilepticusAge groupsNew epilepsy casesObvious underlying etiologyPost-ictal confusionPrevalence of epilepsyComplex partial seizuresRisk of osteoporosisPlasma drug concentrationsCommon underlying causeAdverse eventsOlder patientsPartial seizuresBone healthAntiepileptic drugsCerebrovascular diseaseUnderlying etiologyEpilepsy casesElderly womenPatientsLow dosesEpilepsyNeuropsychiatric disordersDrug concentrations
2003
Novel LGI1 mutation in a family with autosomal dominant partial epilepsy with auditory features
Fertig E, Lincoln A, Martinuzzi A, Mattson R, Hisama F. Novel LGI1 mutation in a family with autosomal dominant partial epilepsy with auditory features. Neurology 2003, 60: 1687-1690. PMID: 12771268, DOI: 10.1212/01.wnl.0000063324.39980.4a.Peer-Reviewed Original ResearchAgedAged, 80 and overAmino Acid SequenceAmino Acid SubstitutionAuditory Perceptual DisordersChromosomes, Human, Pair 10DNA Mutational AnalysisEpilepsy, Temporal LobeExonsFemaleGenes, DominantHumansIntracellular Signaling Peptides and ProteinsItalyMaleMolecular Sequence DataMutation, MissensePedigreePoint MutationProtein Structure, TertiaryProteinsSequence AlignmentSequence Homology, Amino AcidTinnitus
Get In Touch
Contacts
Locations
Yale School of Medicine
Academic Office
Lippard Lab for Clinical Investigation
15 York Street, Ste PO Box 208018
New Haven, CT 06510
Fax
203.737.2799